top of page

Podcast

Oct 15, 2025

Leveraging eSource in clinical data collection with Mats Sundgren

Join Sylvain Berthelot as he welcomes Mats Sundgren, Senior Advisor at the European Institute for Innovation through Health Data. A pioneer in implementing eSource during his years at AstraZeneca, Mats shares how this approach is transforming clinical research.

Together, they explore what eSource really means and why reducing duplicate data entry at site level is such a game-changer. Mats highlights findings from a recent study with Memorial Sloan Kettering Cancer Center, which revealed the heavy time burden manual data entry places on coordinators, and how eSource can dramatically improve efficiency and data quality.

The discussion also covers the promise and challenges of scaling eSource adoption: from interoperability standards like HL7 FHIR, to dealing with unstructured data using natural language processing. Mats emphasizes the role of AI as an assistant rather than a replacement, and why true progress requires aligning value across sponsors, hospitals, vendors, and regulators.

Tune in to learn more about eSource, the cultural shifts needed for sustainable adoption, and the guiding principles Mats applies – rooted in Nash equilibrium.

placeholder_white_300x300.jpg

Share via

See CRScube in action

Explore how our platform will elevate your team and clinical trial management.

crscube_in_action_ca.avif

Get insights straight to your inbox

img_001.avif

Explore our knowledge base

Stay in-the-know with regular updates and industry opinions from our expert team.

Featured resources

icon_01.png

Electronic safety reporting in clinical trials: What sponsors need to know

For sponsors and CROs, it is crucial to understand the implications of the full enforcement of ICH E2B(R3) standards, especially as it impacts both pre- and post-authorization submissions.

icon_01.png

From our sales leaders Juan Munoz-Pujol and Scott Robertson

icon_01.png

Why ICH E2B(R3) still matters in 2026 – A conversation with Ducksang (David) Im

While E2B(R3) standard has existed for some time, global adoption has been gradual. What makes 2026 critical is that many regulatory authorities worldwide have now finalized mandatory transitions.

bottom of page